Fulcrum Financial Statements From 2010 to 2026
| FULC Stock | USD 9.99 0.85 7.84% |
Check Fulcrum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fulcrum Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Fulcrum financial statements analysis is a perfect complement when working with Fulcrum Therapeutics Valuation or Volatility modules.
Check out the analysis of Fulcrum Therapeutics Correlation against competitors. Fulcrum Therapeutics Company Current Valuation Analysis
Fulcrum Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Fulcrum Therapeutics Current Valuation | 526.76 M |
Most of Fulcrum Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fulcrum Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Fulcrum Therapeutics has a Current Valuation of 526.76 M. This is 96.33% lower than that of the Pharmaceuticals sector and 88.66% lower than that of the Health Care industry. The current valuation for all United States stocks is 96.83% higher than that of the company.
Fulcrum Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fulcrum Therapeutics's current stock value. Our valuation model uses many indicators to compare Fulcrum Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fulcrum Therapeutics competition to find correlations between indicators driving Fulcrum Therapeutics's intrinsic value. More Info.Fulcrum Therapeutics is one of the top stocks in return on equity category among its peers. It is rated # 5 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Fulcrum Therapeutics' earnings, one of the primary drivers of an investment's value.About Fulcrum Therapeutics Financial Statements
Fulcrum Therapeutics stakeholders use historical fundamental indicators, such as Fulcrum Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Fulcrum Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Fulcrum Therapeutics' assets and liabilities are reflected in the revenues and expenses on Fulcrum Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Fulcrum Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out the analysis of Fulcrum Therapeutics Correlation against competitors. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.